Filing Details

Accession Number:
0001562180-20-000570
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-01-24 18:43:42
Reporting Period:
2020-01-22
Accepted Time:
2020-01-24 18:43:42
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1689813 Biohaven Pharmaceutical Holding Co Ltd. BHVN () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1262325 Eric Aguiar C/O Aisling Capital Llc
888 Seventh Avenue, 12Th Floor
New York NY 10106
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Acquisiton 2020-01-22 771 $32.42 2,021 No 4 M Indirect By Spouse
Common Shares Acquisiton 2020-01-22 1,250 $37.54 3,271 No 4 M Indirect By Spouse
Common Shares Disposition 2020-01-22 500 $54.97 2,771 No 4 S Indirect By Spouse
Common Shares Disposition 2020-01-22 500 $55.99 2,271 No 4 S Indirect By Spouse
Common Shares Disposition 2020-01-22 671 $56.99 1,600 No 4 S Indirect By Spouse
Common Shares Disposition 2020-01-22 200 $58.00 1,400 No 4 S Indirect By Spouse
Common Shares Disposition 2020-01-22 150 $58.86 1,250 No 4 S Indirect By Spouse
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Indirect By Spouse
No 4 M Indirect By Spouse
No 4 S Indirect By Spouse
No 4 S Indirect By Spouse
No 4 S Indirect By Spouse
No 4 S Indirect By Spouse
No 4 S Indirect By Spouse
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Employee Stock Option (Right to Buy) Disposition 2020-01-22 1,250 $0.00 1,250 $37.54
Common Shares Employee Stock Option (Right to Buy) Disposition 2020-01-22 771 $0.00 771 $32.42
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
2,500 2027-09-04 No 4 M Indirect
22,500 2028-11-19 No 4 M Indirect
Footnotes
  1. These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.38 - $55.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.39 - $56.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.41 - $57.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.70 - $58.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.70 - $59.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
  7. The option, representing a right to purchase a total of 5,000 shares was granted on September 5, 2017, vesting in four equal installments on September 5, 2018, 2019, 2020 and 2021, subject to the option holder's continuous service with the Issuer at each vesting date. The optionholder previously exercised the option with respect to 1,250 shares on November 22, 2019.
  8. This employee stock option is held by the Reporting Person's spouse.
  9. The option, representing a right to purchase a total of 30,000 shares was granted on November 20, 2018, vesting in four equal installments on November 20, 2019, 2020, 2021 and 2022, subject to the option holder's continuous service with the Issuer at each vesting date. The optionholder previously exercised the option with respect to 6,729 shares on November 20, 2019.